Investment
HOIST Corp. Ltd. undergoing Series B financing round
HOIST Corp. Ltd. undergoing Series B financing round
HOIST Corp. Ltd. is a clinical stage biotechnology company established in 2019 based on discoveries from The University of Osaka.
Our projects/technologies include:
HM-001 for bladder cancer (NMIBC)
ALKBH3 inhibitor for pancreatic cancer
Patient derived cells/patent derived xenografts (PDC/PDX)
Business Domain / 分野
Business Type / 業種
Disease Area / 疾患領域
Modalities / モダリティ
Technologies / 技術
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術
Investment
HOIST Corp. Ltd. undergoing Series B financing round
HOIST Corp. Ltd. undergoing Series B financing round
Service
Patient-derived cells (PDC) patient-derived xenografts (PDX) allows you to test the lead compounds before they move into clinical studies.
Partnership
HOIST Corp. Ltd. seeks to license-out rights for HM-001 and ALKBH3 inhibitor
HOIST Corp. Ltd. seeks to license-out rights for a bladder cancer product (HM-001) and a pancreatic cancer product (ALKBH3 inhibitor)